1 / 23

Aggiornamento in Ematologia Clinica

Aggiornamento in Ematologia Clinica. Diagnosi differenziale dei processi linfoproliferativi leucemizzati. Catania, 6-7 novembre 2008.

rwyse
Download Presentation

Aggiornamento in Ematologia Clinica

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aggiornamento in Ematologia Clinica Diagnosi differenziale dei processi linfoproliferativi leucemizzati Catania, 6-7 novembre 2008

  2. FCM studies -> diagnosis of lymphoid neoplasms through the identification of phenotypically abnormal cells belonging to the lymphoid lineage and recognition of phenotypes characteristic of separate disease entities. • FCM can be used to identify expression of targets for potential antibody-directed therapy. • FCM can provide prognostic information such as CD38, ZAP-70 and CD49d expression in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). • Following therapy, flow cytometry is becoming an established method for the evaluation of minimal residual disease.

  3. FCM LYMPHOMA TYPING BLOOD BONE MARROW LYMPH NODES

  4. IgM IgM Natural Abs and IgA B1 cell Germinal centre Marginal zone B cell Proliferation and mutation memory B cell apoptotic cell IgG IgA IgE Follicular B cell Selection and CSR Survival in homing tissues week1 week2 week3

  5. The wrong approach to FCM characterization of NHL This simplistic (and misleading) view of NHL typing is one of the main reasons for the unsufficient scientific communication between histo-pathologists and FCMetrists

  6. CLL MCL PLL FL DLBCL MZL DLBCL LPL BL HCL FL DLBCL HCL FL DLBCL MZL MCL BL MCL CD5+CD10- CD5-CD10+ CD11c+ CD103+ CD25+ CD22++ CD11c+ CD103± CD25+ CD138+ cIg+ sIg- CD138+ CD5+CD10+ CD5-CD10- CD23- CD43+ Bcl-1 CD23- CD43+ Bcl-1

  7. Reagents of clinical utility in mature B-lymphoid neoplasms (from Craig & Foon, 2008, modified)

  8. NOVEL RISK STRATIFICATION: NON-MUTATED VERSUS MUTATED CLL LDT<12 LDT>12 CD38high CD38low Zap-70 high Zap-70 low NM M CD49dhigh CD49dlow CD69 CD71 p53 defects normal p53 poor risk FISH (17p-;11q-) good risk FISH (13q-)

  9. A type of phenotypic aberrancy is abnormal expression of antigens (eg, bcl-2 expression on CD10 B cells). • Normal germinal center B cells and hematogones are both CD10+ and bcl-2-, whereas bcl-2 is expressed by most other B-cell subsets. • Abnormally increased bcl-2 expression can be found in most FL, some diffuse large B-cell lymphoma (DLBCL), and some B-lineage ALL. • In contrast, Burkitt lymphoma (BL) is usually CD10+ and bcl-2-.

  10. FL (bone marrow) B-CELLS T-CELLS PMN 0 1 2 3 4 10 10 10 10 10 BCL2 -> bcl-2/CD3/CD45/CD19

  11. Differential diagnosis between FL and regenerative BM

  12. Identification of composite lymphomas

  13. Structure and expression of CD200 Rosenblum M, Yancey K, Olasz E, Truitt R. J Dermatol Sci 2006;41:165-174

  14. Function of anti-CD200 Treg TH2 CD200+ Tumor Cell TH1

  15. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia • CD200 is OX2 • Membrane gp, Ig superfamily, T and B • Immunosuppressive/ tolerogenic • Myeloma and B-CLL • Cancer stem cells Palumbo GA, Catania

  16. Expression of CD200 in LPD and MM L. Brunetti, ASH 2008

  17. Expression of CD200 in HCL hairy Consistently expressed with high fluorescence intensity

  18. Significance of small populations of phenotypically abnormal B cells. • In the staging of patients with NHL, FCM identification of a small population of abnormal cells can be used to determine the presence of involvement by the neoplasm (particularly if the phenotype matches that of the original diagnostic specimen). • In patients without a previous diagnosis of NHL, the significance of a small population of abnormal B cells (less than 5% of the total cells analyzed) is less clear. • Small populations of B cells with abnormal phenotypes have been reported in peripheral blood and bone marrow specimens, and are not necessarily associated with a diagnosable neoplasm. • Therefore, if a small population of phenotypically abnormal B cells is identified in a patient with no previous diagnosis of a lymphoid neoplasm, it should not be used to establish a new diagnosis of malignancy, but correlated with the morphology, clinical information, and other findings.

  19. A case of MZL

  20. Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma – a new perspective p=0.173 p=0.026 Talaulikar D, Histopathology 2008

  21. HyperCVAD 22 M 18 M % pos cells 0.20 M M 0.10 ABMT 0 Jan 9 Apr 3 Apr 28 Jun 1 Sep 1

  22. Flow cytometry and morphology on the same cell Abnormal localization of selected Antigens David Basiji

  23. Centro di Citometria Clinica e Sperimentale M.Fiammetta Romano Giulia Scalia Rita Bisogni Giovanna Abate Marisa Gorrese Maddalena Raia Ceterina Pascariello Marica Gemei Angela Gravetti Annalisa Di Santi Lorenzo Brunetti

More Related